How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

7,490 results for

Pharmaceutical Representative

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. Petitioning the FDA to Improve Pharmaceutical, Device and Public Health Safety by Ordinary Citizens: A Descriptive Analysis (PubMed)

Petitioning the FDA to Improve Pharmaceutical, Device and Public Health Safety by Ordinary Citizens: A Descriptive Analysis The United States Constitution protects the right of citizens to petition the government for "a redress of grievances." This right has important implications for citizens desiring to advance the public health by petitioning administrative agencies, such as the Food and Drug Administration, to take safety actions. We examined a total of 1,915 petitions filed between 2001 (...) majority of the approved requests included some form of risk communication, such as labeling changes, boxed warnings or placement of a drug into a Risk Evaluation and Mitigation Strategy. As a policy instrument to improve the safety of medical and food products, the citizen petition process requires sophisticated legal and scientific expertise, and may not represent a viable route for ordinary citizens to petition the FDA to "redress grievances."

Full Text available with Trip Pro

2016 PloS one

102. Pharmaceutical Collaborative Care Integrated to a Multidisciplinary Psychosocial Program

Pharmaceutical Collaborative Care Integrated to a Multidisciplinary Psychosocial Program Pharmaceutical Collaborative Care Integrated to a Multidisciplinary Psychosocial Program - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies (...) before adding more. Pharmaceutical Collaborative Care Integrated to a Multidisciplinary Psychosocial Program (PHARMAID) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT02802371 Recruitment Status : Recruiting First Posted

2016 Clinical Trials

103. Systematic review: treatment pattern and clinical effectiveness and safety of pharmaceutical therapies for Crohn's disease in Europe. (PubMed)

Systematic review: treatment pattern and clinical effectiveness and safety of pharmaceutical therapies for Crohn's disease in Europe. Although many clinical trials have been conducted in treatments of Crohn's disease (CD), whether the trial results were representative of daily practice needs to be supported by studies conducted in real-world settings.This study aims to identify how CD is treated and what are the clinical effectiveness and safety of the pharmaceutical therapies of CD in real (...) -world settings.A systematic literature review was conducted based on Medline®, Embase®, and Cochrane. All publications were assessed for title/abstract and full-text according to a predefined study protocol. Data were extracted and reported.A total of 1,998 publications were identified. Fifty studies including six publications reporting treatment pattern and 44 studies reporting clinical effectiveness and safety of pharmaceutical therapies in CD management in Europe were included. 5-Aminosalicylic

Full Text available with Trip Pro

2016 Clinical and experimental gastroenterology

104. Comparison of pharmaceutical, illicit drug, alcohol, nicotine and caffeine levels in wastewater with sale, seizure and consumption data for 8 European cities. (PubMed)

-based epidemiology (WBE) has been shown to be a reliable approach complementing such surveys.This study aims to compare and correlate the consumption estimates of pharmaceuticals, illicit drugs, alcohol, nicotine and caffeine from wastewater analysis and other sources of information. Wastewater samples were collected in 2015 from 8 different European cities over a one week period, representing a population of approximately 5 million people. Published pharmaceutical sale, illicit drug seizure (...) Comparison of pharmaceutical, illicit drug, alcohol, nicotine and caffeine levels in wastewater with sale, seizure and consumption data for 8 European cities. Monitoring the scale of pharmaceuticals, illicit and licit drugs consumption is important to assess the needs of law enforcement and public health, and provides more information about the different trends within different countries. Community drug use patterns are usually described by national surveys, sales and seizure data. Wastewater

Full Text available with Trip Pro

2016 BMC Public Health

105. Pharmaceutical Industry-Sponsored Meals and Physician Prescribing Patterns for Medicare Beneficiaries. (PubMed)

Pharmaceutical Industry-Sponsored Meals and Physician Prescribing Patterns for Medicare Beneficiaries. The association between industry payments to physicians and prescribing rates of the brand-name medications that are being promoted is controversial. In the United States, industry payment data and Medicare prescribing records recently became publicly available.To study the association between physicians' receipt of industry-sponsored meals, which account for roughly 80% of the total number (...) with alternatives in the same class, after adjustment for physician prescribing volume, demographic characteristics, specialty, and practice setting.A total of 279 669 physicians received 63 524 payments associated with the 4 target drugs. Ninety-five percent of payments were meals, with a mean value of less than $20. Rosuvastatin represented 8.8% (SD, 9.9%) of statin prescriptions; nebivolol represented 3.3% (7.4%) of cardioselective β-blocker prescriptions; olmesartan represented 1.6% (3.9%) of ACE inhibitor

Full Text available with Trip Pro

2016 JAMA Internal Medicine

106. Australian University Students’ Coping Strategies and Use of Pharmaceutical Stimulants as Cognitive Enhancers (PubMed)

Australian University Students’ Coping Strategies and Use of Pharmaceutical Stimulants as Cognitive Enhancers There are reports that some university students are using prescription stimulants for non-medical 'pharmaceutical cognitive enhancement (PCE)' to improve alertness, focus, memory, and mood in an attempt to manage the demands of study at university. Purported demand for PCEs in academic contexts have been based on incomplete understandings of student motivations, and often based (...) on untested assumptions about the context within which stimulants are used. They may represent attempts to cope with biopsychosocial stressors in university life by offsetting students' inadequate coping responses, which in turn may affect their cognitive performance. This study aimed to identify (a) what strategies students adopted to cope with the stress of university life and, (b) to assess whether students who have used stimulants for PCE exhibit particular stress or coping patterns.We interviewed 38

Full Text available with Trip Pro

2016 Frontiers in psychology

107. A surefire way to see pharmaceutical reps in a timely fashion

A surefire way to see pharmaceutical reps in a timely fashion A surefire way to see pharmaceutical reps in a timely fashion A surefire way to see pharmaceutical reps in a timely fashion | | January 4, 2016 29 Shares Today so many physicians are not able to see pharmaceutical representatives (PRs). However, PRs do serve as a great resource and finding a way to make their visits more efficient and focused is an objective we all need to strive for. I recall requesting an interview with Lou Holtz (...) be used with pharmaceutical representatives. When a representative comes to the office and asks to see the doctor, they are given a note that I can meet with them but ask them to complete a form listing the three issues or details they would like to discuss and the form asks if they can accomplish this in 7.5 minutes. (I like to provide an odd number so they know I will be checking my watch.) I also have an hourglass that I flip over just to remind them that they are “on the clock” or “in the sand

2016 KevinMD blog

108. Pharmaceutical industry exposure in our hospitals: the final frontier. (PubMed)

believe they are able to effectively manage pharmaceutical sales representative interactions such that their own prescribing is not adversely impacted. Doctors also share a belief that small gifts and benefits are harmless. There may be significant financial burden associated with divestment of such sponsorship by hospitals. Change requires education and effective policies to manage pharmaceutical industry relationships and conflicts of interest. We discuss case studies involving students and public (...) Pharmaceutical industry exposure in our hospitals: the final frontier. Despite recent changes in attitudes, most hospitals continue to experience pharmaceutical industry presence. Pharmaceutical industry presence may be necessary and beneficial in the context of sponsorship of clinical trials with appropriate governance. Doctors continue to hold positive attitudes towards market-oriented activities of the pharmaceutical and medical device industries. Despite evidence to the contrary, doctors

2016 Medical Journal of Australia

109. Effects of Physician-directed Pharmaceutical Promotion on Prescription Behaviors: Longitudinal Evidence. (PubMed)

Effects of Physician-directed Pharmaceutical Promotion on Prescription Behaviors: Longitudinal Evidence. Spending on prescription drugs (Rx) represents one of the fastest growing components of US healthcare spending and has coincided with an expansion of pharmaceutical promotional spending. Most (83%) of Rx promotion is directed at physicians in the form of visits by pharmaceutical representatives (known as detailing) and drug samples provided to physicians' offices. Such promotion has come (...) under increased public scrutiny, with critics contending that physician-directed promotion may play a role in raising healthcare costs and may unduly affect physicians' prescribing habits towards more expensive, and possibly less cost-effective, drugs. In this study, we bring longitudinal evidence to bear upon the question of how detailing impacts physicians' prescribing behaviors. Specifically, we examine prescriptions and promotion for a particular drug class based on a nationally representative

2016 Health economics

110. Minorities are Underrepresented in Clinical Trials of Pharmaceutical Agents for Cystic Fibrosis. (PubMed)

Minorities are Underrepresented in Clinical Trials of Pharmaceutical Agents for Cystic Fibrosis. Members of racial or ethnic minorities make up an appreciable proportion of patients with cystic fibrosis (CF) and have worse outcomes than non-Latino white individuals. Between 1,999 and 2014, the CF Foundation Patient Registry reported an increase in minorities from 5 to 8.2% for Latinos, from 3 to 4.6% for black individuals and from 1.4 to 3.1% for "Other."To evaluate the representation of racial (...) and ethnic minorities in pharmacology clinical trials for CF.We analyzed pharmacology clinical trials in CF published between 1999 and 2015 by searching PubMed and published study reference lists for qualifying study reports. We examined whether the race and ethnicity of study subjects were reported and, if so, what percentage of subjects represented major minority groups.Among 147 pharmacology clinical trials, only 19.7% reported the race or ethnicity of study subjects. Latinos were verified as included

Full Text available with Trip Pro

2016 Annals of the American Thoracic Society

111. PNAUM: integrated approach to Pharmaceutical Services, Science, Technology and Innovation (PubMed)

of the National Policy for Science, Technology and Innovation in Health in Brazil and the National Policy for Pharmaceutical Services. On presenting pharmaceutical policy guidelines, it stresses the lack of nationwide data. This survey, commissioned by the Brazilian Ministry of Health, has two components: household survey and evaluation of pharmaceutical services in primary care. The findings point to perspectives that represent, besides the enhancement of public policy for pharmaceutical services and public (...) PNAUM: integrated approach to Pharmaceutical Services, Science, Technology and Innovation This paper describes the development process of the Pesquisa Nacional sobre Acesso, Utilização e Promoção do Uso Racional de Medicamentos (PNAUM - National Survey on Access, Use and Promotion of Rational Use of Medicines) based on an integrated approach to pharmaceutical services, science, technology and innovation. It starts by contextualizing health and development in Brazil and features elements

Full Text available with Trip Pro

2016 Revista de saúde pública

112. Novel pharmaceutical treatments for minimal traumatic brain injury and evaluation of animal models and methodologies supporting their development (PubMed)

Novel pharmaceutical treatments for minimal traumatic brain injury and evaluation of animal models and methodologies supporting their development The need for effective pharmaceuticals within animal models of traumatic brain injury (TBI) continues to be paramount, as TBI remains the major cause of brain damage for children and young adults. While preventative measures may act to reduce the incidence of initial blunt trauma, well-tolerated drugs are needed to target the neurologically damaging (...) internal cascade of molecular mechanisms that follow. Such processes, known collectively as the secondary injury phase, include inflammation, excitotoxicity, and apoptosis among other changes still subject to research. In this article positive treatment findings to mitigate this secondary injury in rodent TBI models will be overviewed, and include recent studies on Exendin-4, N-Acetyl-l-cycteine, Salubrinal and Thrombin.These studies provide representative examples of methodologies that can be combined

Full Text available with Trip Pro

2016 Journal of neuroscience methods

113. Pharmaceutical expenditure on drugs for rare diseases in Canada: a historical (2007–13) and prospective (2014–18) MIDAS sales data analysis (PubMed)

pharmaceutical drug expenditure (adjusted to 2014 CAD).Between 2007 and 2013, expenditure was measured for a final N = 147 orphan drugs. Orphan drug expenditure totaled $610.2 million (M) in 2007 and $1,100.0 M in 2013, representing 3.3- 5.6 % of total Canadian pharmaceutical drug expenditure in 2007-2013, respectively. Future trend analysis suggests orphan drug expenditure will remain under 6 % of total expenditure in 2014-18.While the number of available orphan drugs and associated expenditure increased (...) Pharmaceutical expenditure on drugs for rare diseases in Canada: a historical (2007–13) and prospective (2014–18) MIDAS sales data analysis Health Canada has defined rare diseases as life-threatening, seriously debilitating, or serious chronic conditions affecting a very small number of patients (~1 in 2,000 persons). An estimated 9 % of Canadians suffer from a rare disease. Drugs treating rare diseases (DRDs) are also known as orphan drugs. While Canada is currently developing an orphan

Full Text available with Trip Pro

2016 Orphanet journal of rare diseases

114. The ridiculous pricing of pharmaceuticals in the U.S.

The ridiculous pricing of pharmaceuticals in the U.S. Dr. Smith's ECG Blog: The ridiculous pricing of pharmaceuticals in the U.S. Sunday, October 4, 2015 I just wrote this letter to my two senators and my representative, and I hope you'll do the same: Dear ________, I practice Emergency Medicine at Hennepin County Medical Center. We have been very adversely affected by the sudden increase in prices of many necessary and previously affordable generic drugs. One example is nitroprusside (brand (...) name Nitropress), which is essential for lowering critically elevated blood pressure. The drug has become unaffordable because Valeant Pharmaceuticals bought the drug and suddenly raised the prices exorbitantly. This company has done the same for many drugs, and other companies have done the same for many others. The only reason this is possible is that the U.S. does not regulate drug prices as all other countries do. Valeant, it turns out, has not only raised all prices, some by as much as 2000

2015 Dr Smith's ECG Blog

115. Pharmaceutical and clinical development of phosphonate-based radiopharmaceuticals for the targeted treatment of bone metastases. (PubMed)

Pharmaceutical and clinical development of phosphonate-based radiopharmaceuticals for the targeted treatment of bone metastases. Therapeutic phosphonate-based radiopharmaceuticals radiolabeled with beta, alpha and conversion electron emitting radioisotopes have been investigated for the targeted treatment of painful bone metastases for >35years. We performed a systematic literature search and focused on the pharmaceutical development, preclinical research and early human studies (...) of 91 phosphonate-based therapeutic radiopharmaceuticals, of which only six agents have progressed to clinical use. Extensive clinical studies have only been described for (186)Re-HEDP, (188)Re-HEDP and (153)Sm-EDTMP. Of these, (153)Sm-EDTMP represents the only compound with worldwide marketing authorization. (177)Lu-EDTMP has recently received approval for clinical use in India. This review illustrates that a thorough understanding of the radiochemistry of these agents is required to design simple

2016 Bone

116. Health-related quality of life and depression among medical sales representatives in Pakistan (PubMed)

Health-related quality of life and depression among medical sales representatives in Pakistan Pharmaceutical companies have been known to pose stress and mental harassment on medical sales representatives (MSRs) in-order to increase pharmaceutical sales. This cross sectional descriptive study, conducted during November and December 2014 in the Lahore and Bahawalpur districts of Punjab, Pakistan, evaluates the Health-Related Quality of Life (HRQoL) and extent of depression among MSRs in Pakistan (...) . The significant predictors of HRQoL and depression among the MSRs were also determined. Using a convenience sampling technique, all consenting MSRs (N = 318) of pharmaceutical companies were asked to self-complete the Short Form-36 (SF-36v2) Health Survey and Stanford Personal Health Questionnaire (PHQ-8). The standard scoring scheme for the SF36v2 and PHQ-8 questionnaires was used. The PHQ-8 scores showed that 16.4 % (n = 52) and 2.5 % of respondents were suffering from major depression and severe major

Full Text available with Trip Pro

2016 SpringerPlus

117. Family doctors' views of pharmaceutical sales representatives: assessment scale development. (PubMed)

Family doctors' views of pharmaceutical sales representatives: assessment scale development. The prescribing patterns depend on the physicians' attitudes and their subjective norms towards prescribing a particular drug, as well as on their personal experience with a particular drug. The physicians are affected by their interactions with pharmaceutical industry.The objectives were to develop a scale for assessment of pharmaceutical sales representatives (PSRs) by the family doctors (FDs

Full Text available with Trip Pro

2011 Family Practice

118. Non-pharmaceutical management of depression

Non-pharmaceutical management of depression Scottish Intercollegiate Guidelines Network Part of NHS Quality Improvement Scotland SIGN Non-pharmaceutical management of depression in adults A national clinical guideline January 2010 114 Help us to improve SIGN guidelines - click here to complete our survey KEY TO EVIDENCE STATEMENTS AND GRADES OF RECOMMENDATIONS LEVELS OF EVIDENCE 1 ++ High quality meta-analyses, systematic reviews of RCTs, or RCTs with a very low risk of bias 1 + Well conducted (...) Guidelines Network Non-pharmaceutical management of depression in adults A national clinical guideline January 2010NoN-pharmaceutical maNagemeNt of depressioN iN adults isBN 978 1 905813 55 1 published January 2010 SIGN consents to the photocopying of this guideline for the purpose of implementation in NHSScotland scottish intercollegiate guidelines Network elliott house, 8 -10 hillside crescent edinburgh eh7 5ea www.sign.ac.ukcontents 1 introduction 1 1.1 Background 1 1.2 The need for a guideline 1 1.3

2010 SIGN

119. Accredited pharmaceutical manufacturers representatives. (PubMed)

Accredited pharmaceutical manufacturers representatives. 455177 1979 09 27 2008 11 20 0008-4409 120 11 1979 Jun 09 Canadian Medical Association journal Can Med Assoc J Accredited pharmaceutical manufacturers representatives. 1327 Bell W W eng Letter Canada Can Med Assoc J 0414110 0008-4409 AIM IM Accreditation Canada Drug Industry 1979 6 9 1979 6 9 0 1 1979 6 9 0 0 ppublish 455177 PMC1819320

Full Text available with Trip Pro

1979 Canadian Medical Association Journal

120. Letter. APMR (Accredited Pharmaceutical Manufacturers Representative). (PubMed)

Letter. APMR (Accredited Pharmaceutical Manufacturers Representative). 4742470 1973 12 12 2008 11 20 0008-4409 109 5 1973 Sep 01 Canadian Medical Association journal Can Med Assoc J Letter. APMR (Accredited Pharmaceutical Manufacturers Representative). 346 passim Eade N R NR eng Journal Article Canada Can Med Assoc J 0414110 0008-4409 AIM IM Canada Certification Drug Industry 1973 9 1 1973 9 1 0 1 1973 9 1 0 0 ppublish 4742470 PMC1946896

Full Text available with Trip Pro

1973 Canadian Medical Association Journal

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>